Why We Invested · OTB Ventures
Why the firm invested
Apheris stands out in the broader data privacy landscape for its ability to deliver a scalable, enterprise-grade product.
Within the broader data privacy landscape, Apheris stands out for its ability to deliver a scalable enterprise-grade product.
Product
Apheris's product is a lightweight software agent serving as a secure gateway between local data and central AI models.
Its product is a lightweight software agent which serves as a secure gateway between local data and central AI models.
Traction
Apheris has signed contracts with several top 20 global pharmaceutical corporations that have deployed the product in live production environments.
This is evidenced by several contracts already signed with several of the world’s top 20 pharmaceutical corporations, who have deployed Apheris in their live production environments.
Team
Due diligence interviews revealed that the team behind Apheris is the primary factor driving its success.
Throughout our due diligence interviews with clients, investors, and other ecosystem participants, one consistent message stood out — while Apheris’ value proposition is compelling on its own, it is the team behind it that ultimately moves the needle.
Investment context
OTB led the Series A round in Apheris alongside eCAPITAL, Octopus Ventures, Heal Capital, and others.
We are delighted to announce that we have led the Series A round in Apheris, an emerging leader in federated AI infrastructure, alongside eCAPITAL, Octopus Ventures, Heal Capital and others.
Marcin Hejka and Mateusz Lukasik from OTB will join Apheris' advisory board.
Marcin Hejka and Mateusz Lukasik from OTB will join Apheris’ advisory board.
What founders can learn
- What actually moved the decision: OTB Ventures wrote that Apheris stands out in the broader data privacy landscape for its ability to deliver a scalable, enterprise-grade product.
- The traction evidence that carried weight: OTB Ventures wrote that Apheris has signed contracts with several top 20 global pharmaceutical corporations that have deployed the product in live production environments.
- How the team was judged: OTB Ventures wrote that Due diligence interviews revealed that the team behind Apheris is the primary factor driving its success.
Source and provenance
Why We Invested published by OTB Ventures on otb.vc (first-party source). Read the original
